Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference
Business Wire - Mon May 12, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 19, 2014, at 8:30 a.m. EDT (1:30 p.m. BST) from the Sheraton New York Hotel. The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Alkermes Earnings In Retrospect: Down 4.6% in the Last 12 Days (ALKS)
Comtex SmarTrend(R) - Mon May 12, 11:47AM CDT
When Alkermes (NASDAQ:ALKS) reported earnings a week ago on April 30th, 2014, analysts, on average, expected the company to report earnings of $0.10 on sales of $138.2 million. Alkermes actually reported earnings of $0.01 per share on sales of $130.2 million, missing EPS estimates by $0.10 and missing revenue estimates by $8.0 million. Shares of Alkermes have slipped from $46.26 to $44.13, representing a loss of 4.6%, since the company reported earnings 12 days ago.
Look for Shares of Alkermes to Potentially Rebound after Yesterday's 1.63% Sell Off
Comtex SmarTrend(R) - Fri May 09, 4:58PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $43.00 to a high of $45.26. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $44.72 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma
PR Newswire - Fri May 09, 12:30PM CDT
On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the day 0.20% higher at 16,550.97, and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished positive. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has advanced 0.78% in the last one month. Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Mast Therapeutics Inc. (NYSE MKT: MSTX), Alkermes PLC (NASDAQ: ALKS) and Momenta Pharmaceuticals Inc. (NASDAQ: MNTA). Free technical research on ACHN, MSTX, ALKS and MNTA can be downloaded upon signing up at:
Schizophrenia - Pipeline Review, H1 2014: 79 Companies Profiled
M2 - Thu May 08, 4:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/49rlth/schizophrenia) has announced the addition of the "Schizophrenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Schizophrenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schizophrenia and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Schizophrenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Schizophrenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Schizophrenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Schizophrenia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - AGY Therapeutics, Inc. - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Acino Pharma AG - Adamed Sp. z o.o. - Addex Therapeutics - Aestus Therapeutics, Inc. - Alkermes Plc - Angita B.V. - Ascendis Pharma A/S - Astellas Pharma Inc. - Athersys, Inc. - BIOPROJET SCR - BRAINco Biopharma, S.L. - BioCrea GmbH - Bionomics Limited - Biotie Therapies Corp. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Cerecor Inc. - Critical Pharmaceuticals Limited - Curemark, LLC - Dainippon Sumitomo Pharma Co., Ltd. - Delpor, Inc. - Domain Therapeutics SA - Dongwha Pharm Co., Ltd. - Echo Pharmaceuticals B.V. - Egis Gyogyszergyar Nyrt - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/49...izophrenia
Drug Addiction - Pipeline Review, H1 2014: 17 Company and 34 Drugs Profiled
M2 - Wed May 07, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sp6lcx/drug_addiction) has announced the addition of the "Drug Addiction - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Drug Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Drug Addiction and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved: - Addex Therapeutics - Alkermes Plc - Aphios Corporation - Biotie Therapies Corp. - Camurus AB - Curemark, LLC - D&A Pharma SAS - Embera NeuroTherapeutics, Inc. - Immunovaccine, Inc. - Kyorin Pharmaceutical Co., Ltd. - Lightlake Therapeutics Inc. - LondonPharma Ltd - Omeros Corporation - Rottapharm|Madaus - SK Biopharmaceuticals Co., Ltd. - Savant HWP, Inc. - Teva Pharmaceutical Industries Limited Drug Profiles: - nepicastat hydrochloride - ibudilast - buprenorphine hydrochloride - SKL-N05 - Butyrylcholinesterase - candesartan cilexetil - baclofen ER - ketamine hydrochloride - (oxazepam metyrapone) - (samidorphan buprenorphine hydrochloride) - LT-22 - ASB - methadone - dronabinol - ADX-88178 - ADX-71441 - OMS-527 - Vaccine For Cocaine Addiction - Cocaine Addiction Vaccine - MH-6 Vaccine - MH-2 [R] Vaccine - Ibogaine Analog - 5HT2 Modulators for CNS and Metabolic Disorders - CM-1212 - methoxycoronaridine - ICKLH-SMO9 Vaccine - N-acetylcystein MGluR5 Antagonist - CR-5542 Series - Small Molecules to Inhibit DAT and SERT for CNS Disorders - Triazole Compounds For more information visit http://www.researchandmarkets.com/research/sp..._addiction
Wider-than-expected Loss at Alkermes, Revenues Slip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 01, 10:50AM CDT
Lower revenues primarily led to the wider loss at Alkermes (ALKS).
Alkermes plc Reports First Quarter 2014 Financial Results
Business Wire - Wed Apr 30, 6:01AM CDT
---- Following Positive Phase 3 Results, Company On Track to Submit New Drug Application for Aripiprazole Lauroxil in Third Quarter of 2014 --
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022
M2 - Tue Apr 29, 8:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/64zc57/pharmapoint) has announced the addition of the "PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2022" report to their offering. Schizophrenia Treatment Market: Novel Products to Provide Slight Boost by 2022, While Unmet Needs Remain The global schizophrenia treatment market value is expected to undergo a modest increase over the coming decade, climbing from $6.3 billion in 2012 to $7.9 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.4%, according to a new report from research and consulting firm The authors. The company's latest report* states that out of the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK and Japan), the US dominated the schizophrenia space in 2012 with sales of $5.2 billion and a global share of 83%. It will maintain its market-leading position by 2022 with sales of $6.1 billion, representing a CAGR of 1.6% during the forecast period. The authors attributes the anticipated market expansion to a rising awareness of mental health, along with increasing utilization of long-acting injectable (LAI) antipsychotics and various new product launches. Among the drugs that are due to enter the market during the forecast period are Otsuka's brexpiprazole, Roche/Chugai's bitopertin, EnVivo's EVP-6124 and Alkermes' aripiprazole lauroxil and Invega Sustenna (Three-Month). Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Janssen Pharmaceuticals - Eli Lilly and Company - Roche - Alkermes - EnVivo Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/64...harmapoint
Global Opioid-Induced Constipation (OIC) Clinical Trials Report 2014 - Analysis of Top 19 Companies/Organisations
M2 - Mon Apr 28, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4gnshl/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014" report to their offering. Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014" provides data on the Opioid-Induced Constipation (OIC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid-Induced Constipation (OIC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid-Induced Constipation (OIC). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Salix Pharmaceuticals Ltd. - AstraZeneca PLC - Mundipharma International Limited - Shionogi & Co., Ltd. - Cubist Pharmaceuticals, Inc. - Theravance, Inc. - Pfizer Inc. - Novartis AG - Alkermes Plc - Alkermes Inc. (Inactive) - Friedrich-Schiller-Universitat Jena - The University of Vermont - St. John's Health System - VU University Medical Center - Shriners Hospitals for Children - Kuopio University Hospital - British Columbia Cancer Agency - UMC Utrecht Holding BV - Ullevaal University Hospital For more information visit http://www.researchandmarkets.com/research/4g...oidinduced
Alkermes to Host Conference Call to Discuss First Quarter 2014 Financial Results
Business Wire - Wed Apr 23, 3:00PM CDT
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Wednesday, April 30, 2014, to discuss the company's financial results for the first quarter of 2014. Management will review the quarter and provide an update on the company.
The Zacks Analyst Blog Highlights:GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics
PR Newswire - Thu Apr 17, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the GIlead (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), MannKind (Nasdaq:MNKD-Free Report), Alkermes (Nasdaq:ALKS-Free Report)andPharmacyclics (Nasdaq
Research and Markets: Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022
Business Wire - Thu Apr 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t528kt/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.
Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022
M2 - Thu Apr 17, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmclnk/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering. Aripiprazole lauroxil is a novel lipid ester prodrug of aripiprazole that utilizes Alkermes' proprietary LinkeRx technology for once-monthly drug delivery. Once administered IM, aripiprazole lauroxil is converted to aripiprazole, a 5-HT2A antagonist/D2 and 5-HT1A partial agonist that is marketed as Abilify by Otsuka. Alkermes' aripiprazole lauroxil differs from Otsuka/Lundbeck's once-monthly formulation of Abilify, called Abilify Depot, in that it is supplied as a suspension and does not require reconstitution prior to administration. Scope - Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Aripiprazole Lauroxil including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Aripiprazole Lauroxil for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms 4 Disease Management 4.1 Diagnosis 4.1.1 Subjective Assessments 4.1.2 Disease Subtypes 4.2 Treatment Overview 4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 4.2.2 Maintenance Treatment of Schizophrenia 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Opportunity and Unmet Need 6.1 Unmet Needs Overview 6.1.1 Public Awareness 6.1.2 Early Diagnosis and Treatment 6.1.3 Long-Acting and Advanced Drug Delivery Systems 6.1.4 Effective Management of Negative and Cognitive Symptom Domains 6.2 Gap Analysis 6.2.1 Long-Acting Drug Delivery 6.2.2 Treatment of Negative and Cognitive Symptoms 7 Pipeline Assessment 7.1 Overview 7.2 Early-Stage Pipeline Assessment 7.3 Novel Therapeutic Approaches 7.3.1 Negative Symptoms 7.3.2 Cognitive Symptoms 7.4 Long-Acting Drug Delivery 7.5 Technology Trends Analysis 7.6 Key Drugs in Clinical Development 8 Aripiprazole Lauroxil 8.1 Overview 8.2 Efficacy 8.3 Safety 8.3.1 Dosing and Formulation 8.3.2 Potential Clinical Positioning 8.3.3 Potential Commercial Positioning 8.3.4 Pricing and Reimbursement 8.4 SWOT Analysis 8.5 Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/bm...ipiprazole
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Another tough week for the biotechnology industry overshadowed impressive clinical results from several companies. Alkermes scored a big win in a difficult indication. Puma Biotechnology announced a high probability of success with its single...
Watch for Alkermes to Potentially Rebound After Falling 1.43% Yesterday
Comtex SmarTrend(R) - Mon Apr 14, 5:17PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $40.57 to a high of $42.82. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $41.61 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.
Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.